ReviewInflammopharmacology2026
Medicinal plants as alternative and adjunct antimicrobial agents in ear, nose, and throat (ENT) Infections.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants are widely used worldwide for ear, nose, and throat (ENT) disorders and have a long history of traditional application. This review aims to summarize current experimental and clinical evidence on medicinal plants used for ENT conditions such as otitis externa/media, tinnitus, vertigo, allergic rhinitis, pharyngitis, and laryngitis, and to support the identification of new plant species with antimicrobial potential against ENT pathogens. This review thoroughly summarizes recent developments from 2020 to 2025 and was conducted using electronic databases, including PubMed, Web of Science, Scopus, ScienceDirect, and Google Scholar, with predefined ENT and medicinal plants-related keywords. Frequently used species include Lavandula angustifolia, Thymus vulgaris, Curcuma longa, Zingiber officinale, Origanum vulgare, Glycyrrhiza glabra, Mentha piperita, Matricaria chamomilla, and Syzygium aromaticum, many of which show In vitro antibacterial, antifungal, or antiviral activity relevant to upper airway and oral/ENT infections. Evidence indicates that selected medicinal plants and their extracts or essential oils inhibit key ENT-related pathogens, including multidrug-resistant respiratory and pharyngeal bacteria. The compiled data, structured in comparative tables, highlight promising taxa and preparation types, and underscore gaps in clinical validation, standardization, and safety assessment. Overall, this review provides an evidence-based overview of ENT-related phytotherapy and a framework for future pharmacological and phytochemical studies aimed at developing novel plant-derived antimicrobials for ear, nose, and throat diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.